Shares of Niagen Bioscience (NASDAQ: NAGE) surged 22.45% in after-hours trading on Wednesday, following the release of the company's impressive second-quarter financial results that significantly exceeded analyst expectations. The biotechnology firm not only reported strong earnings and revenue growth but also raised its full-year outlook, sparking investor enthusiasm.

Niagen Bioscience reported quarterly earnings of $0.04 per share, beating the analyst consensus estimate of $0.02 by a remarkable 122.22%. The company's quarterly sales reached $31.117 million, surpassing the analyst consensus estimate of $28.324 million by 9.86%. This represents a substantial 36.84% increase compared to sales of $22.739 million in the same period last year. The strong performance was underlined by a gross profit of $20.226 million and an operating income of $3.185 million for the quarter.

Adding to the positive sentiment, Niagen Bioscience announced an increase in its full-year outlook, signaling confidence in its growth trajectory. This optimistic forecast, combined with the recent "Buy" rating reiteration from H.C. Wainwright analyst Ram Selvaraju, highlights the company's promising clinical results and strategic IP acquisitions. As Niagen Bioscience continues to demonstrate strong financial performance and strategic growth initiatives, investors appear increasingly bullish on the stock's future prospects.